Date: April 9, 2020

To,
The Manager,
Listing Department,
National Stock Exchange of India Limited,
Exchange Plaza, C-1, Block-G, Bandra-Kurla Complex,
Bandra (E), Mumbai-400 051.

To,
The Department of Corporate Service,
BSE Limited,
1st Floor, New Trading Ring,
Rotunda Building, Phiroze Jeejeebhoy Tower,
Dalal Street, Mumbai-400 001.

Scrip Code – LINCOLN
Scrip Code – 531633

Dear Sir,

Sub: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform that the update on impact of Novel Coronavirus (COVID-19) on the business of the Company as given in “Annexure-A” as given below.

We request you to kindly take the above on record.

Thanking you,

Yours faithfully,

FOR LINCOLN PHARMACEUTICALS LIMITED

Sd/-
NIREN A. DESAI
[COMPANY SECRETARY]

Encl: a/a
Annexure-A

Update on impact of Novel Coronavirus (COVID-19)

Lincoln Pharmaceuticals Limited (“Company”) salutes the entire medical & support fraternity including doctors, nurses, healthcare workers and civil forces who are selflessly providing care to all affected patients in India and also taking a series of measures in view of the COVID-19 pandemic to ensure safety and health of all our employees and to ensure compliance with various directives being issued by Central/State/Municipal authorities. To help these front-line warriors, the company have manufactured high-quality hand sanitizers and will make them available to healthcare professionals serving their communities and the nation.

Despite some supply chain disruptions due to the lockdown period, company is working relentlessly to minimize disruptions in the production and supply schedules to serve the society in this challenging times. Although doing the best we can and putting in place a business continuity plan, we may encounter some delays in the deliveries of products due to the restriction in the movement of goods and employees. The company is working closely with the governments and relevant stakeholders to ensure there is uninterrupted supply of medicines. Company is also constituting a task force to handle the distribution of these products in local supply as well as in India.

Company is committed to fight the COVID-19 pandemic and instructed all its employees to work from home who are able to work remotely at all its locations. The company is proud of its passionate and dedicated team members in Manufacturing, IT, Quality, Finance, HR and Supply Chain, who are working for the company even in the situation of pandemic. Additionally, company has contributed sizable quantum with the primary objective of dealing with any kind of emergency or distress situation by Novel Coronavirus (COVID-19).

Safe Harbor Statement

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential project characteristics, project potential and target dates for project related issues are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. The company assumes no obligation to update forward-looking statements to reflect actual results changed assumptions or other factors.